Genscript Biotech (1548) Stock Overview
An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
1548 Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Genscript Biotech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$17.59 |
| 52 Week High | HK$19.40 |
| 52 Week Low | HK$8.88 |
| Beta | 0.95 |
| 1 Month Change | 5.96% |
| 3 Month Change | 34.48% |
| 1 Year Change | 45.61% |
| 3 Year Change | -24.18% |
| 5 Year Change | 25.82% |
| Change since IPO | 1,232.58% |
Recent News & Updates
Recent updates
Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues
Jul 29
At HK$18.16, Is It Time To Put Genscript Biotech Corporation (HKG:1548) On Your Watch List?
Jul 24
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
May 14Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
Apr 07Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump
Feb 12Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 20Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
Nov 19Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
Oct 01What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Sep 16Shareholder Returns
| 1548 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | -6.1% | 2.7% | -1.8% |
| 1Y | 45.6% | 130.4% | 42.8% |
Return vs Industry: 1548 underperformed the Hong Kong Life Sciences industry which returned 130.4% over the past year.
Return vs Market: 1548 exceeded the Hong Kong Market which returned 42.8% over the past year.
Price Volatility
| 1548 volatility | |
|---|---|
| 1548 Average Weekly Movement | 8.5% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in HK Market | 16.2% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 1548 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1548's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 5,769 | Sherry Shao | www.genscript.com |
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through three segments: Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products. The Life Science Services and Products segment provides products and services in various categories, including gene synthesis, oligonucleotide synthesis, peptide synthesis, protein engineering, antibody development, and life-science equipment and consumables, such as molecular diagnostics tools and genome editing materials for biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and the food industry.
Genscript Biotech Corporation Fundamentals Summary
| 1548 fundamental statistics | |
|---|---|
| Market cap | HK$38.36b |
| Earnings (TTM) | HK$35.73m |
| Revenue (TTM) | HK$6.46b |
Is 1548 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1548 income statement (TTM) | |
|---|---|
| Revenue | US$828.10m |
| Cost of Revenue | US$368.85m |
| Gross Profit | US$459.25m |
| Other Expenses | US$454.67m |
| Earnings | US$4.58m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0021 |
| Gross Margin | 55.46% |
| Net Profit Margin | 0.55% |
| Debt/Equity Ratio | 11.0% |
How did 1548 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/02 17:13 |
| End of Day Share Price | 2025/09/02 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genscript Biotech Corporation is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Shitong Han | Citic Securities Co., Ltd. |
| Zhu Chen | Citic Securities Co., Ltd. |